相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer
M. Chiappa et al.
DRUG RESISTANCE UPDATES (2021)
Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance
Dae-Seok Kim et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2021)
Successful treatment of a patient with brain metastases from endometrial cancer using Niraparib: a case report
Qing Wang et al.
ANNALS OF PALLIATIVE MEDICINE (2021)
Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer
Feiyue Zheng et al.
BIOMEDICINE & PHARMACOTHERAPY (2020)
Niraparib as Maintenance Therapy in Germline ATM-mutated and Somatic BRCA2-mutated Ovarian Cancer with Brain Metastases: A Case Report and Literature Review
Mengyu Tao et al.
ONCOTARGETS AND THERAPY (2020)
The blood-brain barrier and blood-tumour barrier in brain tumours and metastases
Costas D. Arvanitis et al.
NATURE REVIEWS CANCER (2020)
PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms
Xuan Jiang et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2019)
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial
Kathleen N. Moore et al.
LANCET ONCOLOGY (2019)
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
A. Gonzalez-Martin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Current trends in drug metabolism and pharmacokinetics
Yuhua Li et al.
ACTA PHARMACEUTICA SINICA B (2019)
Intracranial evaluation of the in vivo pharmacokinetics, brain distribution, and efficacy of rucaparib in BRCA-mutant, triple-negative breast cancer
Minh Nguyen et al.
CANCER RESEARCH (2019)
Efficacy and pharmacodynamics of niraparib in BRCA-mutant and wild-type intracranial triple-negative breast cancer murine models
Maria J. Sambade et al.
NEURO-ONCOLOGY ADVANCES (2019)
Niraparib as maintenance therapy in a patient with ovarian cancer and brain metastases
Simon Gray et al.
BMJ CASE REPORTS (2019)
A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models
Kaiming Sun et al.
Oncotarget (2018)
Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a 14C-microtracer and therapeutic dose in cancer patients
L. van Andel et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2018)
Therapeutic Potential and Utility of Elacridar with Respect to P-glycoprotein Inhibition: An Insight from the Published In Vitro, Preclinical and Clinical Studies
Ranjeet Prasad Dash et al.
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS (2017)
Obstacles to Brain Tumor Therapy: Key ABC Transporters
Juwina Wijaya et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Human mass balance study and metabolite profiling of 14C-niraparib, a novel poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer
Lotte van Andel et al.
INVESTIGATIONAL NEW DRUGS (2017)
Liquid chromatography-tandem mass spectrometry assay for the quantification of niraparib and its metabolite M1 in human plasma and urine
L. van Andel et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2017)
A CRISPR-Cas9 Generated MDCK Cell Line Expressing Human MDR1 Without Endogenous Canine MDR1 (cABCB1): An Improved Tool for Drug Efflux Studies
Maria Karlgren et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2017)
PARP inhibitors: Synthetic lethality in the clinic
Christopher J. Lord et al.
SCIENCE (2017)
In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma
Mariam M. AlHilli et al.
GYNECOLOGIC ONCOLOGY (2016)
Role of Organic Anion-Transporting Polypeptides (OATPs) in Cancer Therapy
Nilay Thakkar et al.
AAPS JOURNAL (2015)
Overcoming the blood-brain tumor barrier for effective glioblastoma treatment
O. van Tellingen et al.
DRUG RESISTANCE UPDATES (2015)
Molecular Pathways: How Can BRCA-Mutated Tumors Become Resistant to PARP Inhibitors?
Peter Bouwman et al.
CLINICAL CANCER RESEARCH (2014)
ABC Transporters in Multidrug Resistance and Pharmacokinetics, and Strategies for Drug Development
Young Hee Choi et al.
CURRENT PHARMACEUTICAL DESIGN (2014)
The SLCO (former SLC21) superfamily of transporters
Bruno Hagenbuch et al.
MOLECULAR ASPECTS OF MEDICINE (2013)
Murine Oatp1a/1b Uptake Transporters Control Rosuvastatin Systemic Exposure Without Affecting Its Apparent Liver Exposures
Dilek Iusuf et al.
MOLECULAR PHARMACOLOGY (2013)
The Blood-Brain Barrier: Its Influence in the Treatment of Brain Tumors Metastases
D. Fortin
CURRENT CANCER DRUG TARGETS (2012)
Quantitative Proteomics of Transporter Expression in Brain Capillary Endothelial Cells Isolated from P-Glycoprotein (P-gp), Breast Cancer Resistance Protein (Bcrp), and P-gp/Bcrp Knockout Mice
Sagar Agarwal et al.
DRUG METABOLISM AND DISPOSITION (2012)
Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors
Yasuo Uchida et al.
JOURNAL OF NEUROCHEMISTRY (2011)
Double-Transduced MDCKII Cells To Study Human P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) Interplay in Drug Transport across the Blood-Brain Barrier
Birk Poller et al.
MOLECULAR PHARMACEUTICS (2011)
PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel
Yong Zhang et al.
COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE (2010)
Organic anion transporting polypeptide 1a/1b-knockout mice provide insights into hepatic handling of bilirubin, bile acids, and drugs
Evita van de Steeg et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Membrane transporters in drug development
Kathleen M. Giacomini et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
ABC transporters in cancer: more than just drug efflux pumps
Jamie I. Fletcher et al.
NATURE REVIEWS CANCER (2010)
Physiological and pharmacological roles of ABCG2 (BCRP): Recent findings in Abcg2 knockout mice
Maria L. H. Vlaming et al.
ADVANCED DRUG DELIVERY REVIEWS (2009)
Impact of OATP transporters on pharmacokinetics
A. Kalliokoski et al.
BRITISH JOURNAL OF PHARMACOLOGY (2009)
Importance of knowledge on drug metabolism for the safe use of drugs in humans
Franz Oesch
DRUG METABOLISM REVIEWS (2009)
Discovery of 2-{4-[(3S)-Piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): A Novel Oral Poly(ADP-ribose)polymerase (PARP) Inhibitor Efficacious in BRCA-1 and-2 Mutant Tumors
Philip Jones et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Impact of Genetic Polymorphisms of Transporters on the Pharmacokinetic, Pharmacodynamic and Toxicological Properties of Anionic Drugs
Kazuya Maeda et al.
DRUG METABOLISM AND PHARMACOKINETICS (2008)
Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism
Antonius E. van Herwaarden et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs
Ingolf Cascorbi
PHARMACOLOGY & THERAPEUTICS (2006)
Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters
Supratim Choudhuri et al.
INTERNATIONAL JOURNAL OF TOXICOLOGY (2006)
Contribution of the ABC transporters Bcrp1 and Mdr1a/1b to the side population phenotype in mammary gland and bone marrow of mice
JW Jonker et al.
STEM CELLS (2005)
Preclinical pharmacokinetic properties of the P-glycoprotein inhibitor GF120918A (HCl salt of GF120918, 9,10-dihydro-5-methoxy-9-oxo-N-[4-[ 2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]phenyl]-4-acridine-carboxamide) in the mouse, rat, dog, and monkey
KW Ward et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2004)
Genetic contribution to variable human CYP3A-mediated metabolism
JK Lamba et al.
ADVANCED DRUG DELIVERY REVIEWS (2002)
Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan
JW Jonker et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition
GK Dresser et al.
CLINICAL PHARMACOKINETICS (2000)
分享论文
